EZH2: an epigenetic gatekeeper promoting lymphomagenesis.

[1]  O. Elemento,et al.  EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. , 2013, Cancer cell.

[2]  O. Elemento,et al.  Aberration in DNA Methylation in B-Cell Lymphomas Has a Complex Origin and Increases with Disease Severity , 2013, PLoS genetics.

[3]  M. Esteller,et al.  Genome-wide DNA methylation profiling predicts relapse in childhood B-cell acute lymphoblastic leukaemia , 2012, British journal of haematology.

[4]  Yan Liu,et al.  EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations , 2012, Nature.

[5]  M. Robinson,et al.  Bisulfite sequencing of chromatin immunoprecipitated DNA (BisChIP-seq) directly informs methylation status of histone-modified DNA , 2012, Genome research.

[6]  Steven J. M. Jones,et al.  Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.

[7]  O. Elemento,et al.  EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. , 2010, Blood.

[8]  Zohar Yakhini,et al.  Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer , 2007, Nature Genetics.

[9]  M. Fraga,et al.  The novel DNA methylation inhibitor zebularine is effective against the development of murine T-cell lymphoma. , 2006, Blood.

[10]  C. Meijer,et al.  Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. , 2001, Blood.